Federal Grant Award Summary

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $720,021 Project Grant to the University of California, San Diego under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 6, 2026, with a completion date of January 31, 2031. This research initiative focuses on developing broadly protective immunization strategies against Group A Streptococcus (Strep A) by designing M protein-based immunogens that elicit cross-reactive antibodies effective against diverse Strep A strains. The project builds upon structural and functional discoveries to identify conserved three-dimensional patterns in M proteins that mediate binding to human C4B-binding protein, a key virulence factor. Researchers will leverage findings from the Phase I trial immunogen StreptaNova and recent identification of a C4BP-binding pattern in M22 protein to develop enhanced immunogens with improved M-type cross-reactivity.

The research encompasses both basic scientific investigation and translational vaccine development activities conducted at UC San Diego's La Jolla campus, with collaborative support from international partners including Lund University in Sweden. Expected deliverables include structural characterization of M protein-antibody interactions, identification of cross-reactive epitopes, development and testing of M-based immunogen candidates, and generation of opsonophagocytic antibody data to support continued advancement toward clinical vaccine candidates addressing this significant global pathogen responsible for substantial morbidity and mortality.